Analysts expect Q1 2026 revenue of $12.17 billion, up 15.4% year-over-year, aligning closely with Netflix's guidance of $12.16 billion. Consensus EPS estimate stands at $0.76, matching the company's outlook and reflecting 15% growth from Q1 2025's $0.66.

Analysts expect Q1 2026 EPS of $3.29, up 55% year-over-year from $2.12. Consensus revenue forecast at $35.5 billion, aligning with TSMC's guidance of $34.6-35.8 billion and implying 39% growth.

JPMorgan Chase reported Q1 2026 net income of $16.5 billion, up 13% year-over-year. Diluted EPS came in at $5.94, surpassing consensus estimates of $5.49 by 8%.

Johnson & Johnson reported Q1 2026 sales of $24.1 billion, up 9.9% year-over-year, beating consensus estimates of $23.6 billion. Adjusted EPS came in at $2.70, surpassing expectations of $2.68 and down 2.5% from $2.77 in Q1 2025.

Wells Fargo reported Q1 2026 net income of $5.3 billion, up 7% year-over-year, with diluted EPS of $1.60 beating consensus estimates of $1.58. Total revenue reached $21.45 billion, a 6% increase from Q1 2025 but missing expectations of $21.76 billion, driven by 5% net interest income growth and 8% noninterest income rise.

Citigroup reported Q1 2026 net income of $5.8 billion, up 42% from $4.1 billion in Q1 2025, with diluted EPS of $3.06 versus consensus estimates of $2.63. Revenues hit $24.6 billion, the highest in a decade and up 14% year-over-year, beating expectations of approximately $23.5 billion.

BlackRock reported Q1 2026 revenue of $6.70 billion, up 27% year-over-year and beating consensus estimates of $6.56 billion. Adjusted diluted EPS came in at $12.53, surpassing expectations of $12.40 and up 11% from $11.30 a year ago.

Albertsons reported Q4 fiscal 2025 net sales and other revenue of $20.3 billion, up from $18.8 billion in the prior-year 12-week period, boosted by a 53rd week. Identical sales grew 0.7%, pressured by pharmacy headwinds from the Inflation Reduction Act (IRA, a U.

CarMax reported Q4 net loss per diluted share of $0.85, impacted by $0.99 non-cash goodwill impairment and $0.20 restructuring charges; adjusted EPS of $0.34 beat Zacks Consensus Estimate of $0.22 by 57.63%. Net sales and operating revenues of $5.95 billion, down 1% YoY but exceeded estimates by 3.01%.

Nurix Therapeutics reported fiscal first quarter 2026 revenue of $6.3 million, down from $18.5 million a year ago due to the end of initial research terms in the Sanofi collaboration. Net loss widened to $87.2 million, or ($0.79) per share, compared to $56.4 million, or ($0.67) per share, in the prior-year quarter; EPS missed consensus estimates of ($0.76).

Analysts expect Q1 2026 EPS of $0.94, down from $1.09 in Q4 2025. Consensus revenue forecast stands at $2.14 billion, slightly below Q4's $2.17 billion.

Analysts expect Q1 2026 EPS of around $1.78-$1.93, down from $2.15 in Q1 2025 amid seasonally weaker margins. Revenue consensus at approximately $2.61 billion, slightly below Q1 2025's $2.58 billion.

Analysts expect Q1 2026 EPS of $1.20-$1.22, down about 8% from $1.30 reported in Q1 2025. Consensus revenue forecast around $231-232 million, up roughly 4% year-over-year from $222 million.

Analysts expect Q1 2026 EPS of approximately $2.66, up from $2.57 in Q1 2025. Revenue consensus hovers around $154-157 million, reflecting steady banking operations.

GOLD stock declined approximately -12% over the past 30 days amid a pullback in gold prices and sector volatility. Over the past quarter, the stock is up roughly +10%, supported by strong revenue growth and acquisitions.

CLLS stock rose +18% over the last 30 days, driven by positive interim clinical data from partnered programs and strong Q4 2025 earnings beat. Over the past quarter, shares declined -5%, reflecting biotech sector volatility amid ongoing arbitration resolutions and pipeline developments.

Analysts expect Q1 2026 EPS of $1.93, a 22% year-over-year increase from $1.58. Revenue consensus stands at $5.15 billion, up 7.5% from $4.79 billion in Q1 2025.

Analysts expect Q1 2026 EPS of around $6.80, a 256% surge from $1.91 core EPS in Q1 2025. Consensus revenue forecast stands at $12.34 billion, up about 4% year-over-year.

Analysts expect Q1 2026 EPS of $1.13-$1.14, a 9.7%-10.7% increase from $1.03 in Q1 2025. Consensus revenue forecast stands at $7.27-$7.3 billion, up about 4.9% year-over-year.

Riley Exploration Permian, Inc. (REPX) is down 13.02% in today’s session, trading around $35.00 versus yesterday’s close of $40.26. The drop comes just one day after REPX hit a new 52‑week high of $41.26, extending a rally of more than 70% over the past 12 months and leaving the stock vulnerable to profit‑taking.